Shortening Duration of Therapy With DAAs for HCV Genotype 1 Shortening Duration of Therapy With DAAs for HCV Genotype 1

Can direct-acting antiviral therapy for hepatitis C genotype 1 be reduced to less than the current standard of 12 weeks without compromising outcomes?Journal of Viral Hepatitis
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news